| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 34 | 2023 | 221 | 9.730 |
Why?
|
| Heart Failure | 47 | 2023 | 1180 | 8.590 |
Why?
|
| Ventricular Dysfunction, Right | 12 | 2023 | 117 | 3.940 |
Why?
|
| Hypertension, Pulmonary | 15 | 2021 | 232 | 3.380 |
Why?
|
| Pulmonary Wedge Pressure | 13 | 2022 | 102 | 3.230 |
Why?
|
| Hemodynamics | 16 | 2022 | 705 | 3.130 |
Why?
|
| Heart Transplantation | 15 | 2022 | 328 | 2.930 |
Why?
|
| Ventricular Function, Right | 10 | 2021 | 103 | 2.440 |
Why?
|
| Heart Ventricles | 10 | 2021 | 738 | 2.090 |
Why?
|
| Cardiac Catheterization | 10 | 2021 | 419 | 1.630 |
Why?
|
| Pulmonary Artery | 9 | 2020 | 323 | 1.450 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2019 | 185 | 1.210 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 119 | 1.200 |
Why?
|
| Humans | 81 | 2023 | 68618 | 1.100 |
Why?
|
| Cardiomyopathies | 4 | 2022 | 167 | 1.000 |
Why?
|
| Vasodilator Agents | 4 | 2022 | 138 | 0.950 |
Why?
|
| Middle Aged | 35 | 2021 | 21147 | 0.790 |
Why?
|
| Vascular Resistance | 8 | 2021 | 179 | 0.790 |
Why?
|
| Retrospective Studies | 29 | 2022 | 7277 | 0.770 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 277 | 0.750 |
Why?
|
| Stroke Volume | 8 | 2022 | 586 | 0.740 |
Why?
|
| Arteriovenous Malformations | 2 | 2019 | 34 | 0.720 |
Why?
|
| Electrocardiography | 3 | 2021 | 601 | 0.710 |
Why?
|
| Male | 39 | 2021 | 37321 | 0.710 |
Why?
|
| Exercise Tolerance | 3 | 2021 | 75 | 0.690 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2019 | 9 | 0.680 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2019 | 155 | 0.680 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 514 | 0.680 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 202 | 0.680 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.670 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 481 | 0.660 |
Why?
|
| Prosthesis Implantation | 3 | 2018 | 83 | 0.650 |
Why?
|
| Pulmonary Ventilation | 1 | 2018 | 28 | 0.650 |
Why?
|
| Endothelin-1 | 1 | 2020 | 122 | 0.640 |
Why?
|
| Female | 39 | 2022 | 38074 | 0.630 |
Why?
|
| Shock, Cardiogenic | 1 | 2018 | 23 | 0.620 |
Why?
|
| Bundle-Branch Block | 1 | 2018 | 50 | 0.610 |
Why?
|
| Pericardial Effusion | 2 | 2016 | 15 | 0.610 |
Why?
|
| RNA, Transfer, Leu | 1 | 2017 | 5 | 0.590 |
Why?
|
| Genes, Mitochondrial | 1 | 2017 | 4 | 0.590 |
Why?
|
| Bartonella henselae | 1 | 2017 | 9 | 0.590 |
Why?
|
| Cat-Scratch Disease | 1 | 2017 | 10 | 0.590 |
Why?
|
| Leukoencephalopathies | 1 | 2017 | 13 | 0.580 |
Why?
|
| Risk Assessment | 3 | 2019 | 2007 | 0.560 |
Why?
|
| Erdheim-Chester Disease | 1 | 2016 | 2 | 0.540 |
Why?
|
| Registries | 6 | 2022 | 733 | 0.520 |
Why?
|
| Dobutamine | 1 | 2015 | 25 | 0.500 |
Why?
|
| Endarterectomy | 1 | 2015 | 22 | 0.500 |
Why?
|
| Bone and Bones | 1 | 2016 | 145 | 0.500 |
Why?
|
| Pseudopseudohypoparathyroidism | 1 | 2014 | 1 | 0.500 |
Why?
|
| Hand Bones | 1 | 2014 | 1 | 0.500 |
Why?
|
| Pseudohypoparathyroidism | 1 | 2014 | 3 | 0.500 |
Why?
|
| Mutation | 2 | 2017 | 1213 | 0.490 |
Why?
|
| Fatigue | 1 | 2016 | 132 | 0.490 |
Why?
|
| Thigh | 1 | 2014 | 27 | 0.480 |
Why?
|
| Hyperpigmentation | 1 | 2014 | 7 | 0.480 |
Why?
|
| Rheumatoid Factor | 1 | 2014 | 21 | 0.480 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2014 | 15 | 0.480 |
Why?
|
| Melena | 1 | 2014 | 8 | 0.480 |
Why?
|
| Enteritis | 1 | 2014 | 6 | 0.480 |
Why?
|
| Aged | 19 | 2021 | 14862 | 0.460 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 40 | 0.460 |
Why?
|
| Fever | 1 | 2014 | 96 | 0.450 |
Why?
|
| Cytomegalovirus Infections | 1 | 2014 | 69 | 0.450 |
Why?
|
| Echocardiography | 7 | 2022 | 515 | 0.440 |
Why?
|
| Treatment Outcome | 15 | 2022 | 7029 | 0.440 |
Why?
|
| Abdominal Pain | 1 | 2014 | 97 | 0.440 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 157 | 0.430 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 253 | 0.420 |
Why?
|
| Lung Diseases | 1 | 2014 | 175 | 0.410 |
Why?
|
| Metabolomics | 1 | 2012 | 28 | 0.410 |
Why?
|
| Blood Pressure | 2 | 2017 | 1451 | 0.410 |
Why?
|
| Prognosis | 11 | 2022 | 2093 | 0.400 |
Why?
|
| Arterial Pressure | 3 | 2020 | 47 | 0.390 |
Why?
|
| Adult | 22 | 2022 | 21403 | 0.390 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 71 | 0.390 |
Why?
|
| Autoantibodies | 1 | 2014 | 434 | 0.390 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 207 | 0.390 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2011 | 1 | 0.390 |
Why?
|
| Hyperammonemia | 1 | 2011 | 4 | 0.390 |
Why?
|
| Brain Edema | 1 | 2011 | 50 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.360 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 597 | 0.360 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2021 | 174 | 0.350 |
Why?
|
| Myocardial Contraction | 2 | 2021 | 383 | 0.330 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 219 | 0.330 |
Why?
|
| Sarcoidosis | 2 | 2021 | 77 | 0.330 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 161 | 0.320 |
Why?
|
| Risk Factors | 8 | 2022 | 5731 | 0.310 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 940 | 0.300 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 756 | 0.300 |
Why?
|
| Cardiac Output | 3 | 2022 | 133 | 0.290 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1140 | 0.270 |
Why?
|
| Prospective Studies | 7 | 2022 | 3705 | 0.270 |
Why?
|
| Disease Progression | 3 | 2019 | 1038 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3259 | 0.250 |
Why?
|
| Lymph Nodes | 2 | 2017 | 258 | 0.240 |
Why?
|
| Nitroprusside | 2 | 2022 | 42 | 0.240 |
Why?
|
| Weight Loss | 2 | 2017 | 319 | 0.230 |
Why?
|
| United States | 8 | 2022 | 7367 | 0.230 |
Why?
|
| Oxygen Consumption | 2 | 2022 | 258 | 0.230 |
Why?
|
| Biopsy | 2 | 2017 | 540 | 0.230 |
Why?
|
| Heart Atria | 2 | 2022 | 206 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 772 | 0.220 |
Why?
|
| Waiting Lists | 3 | 2021 | 104 | 0.220 |
Why?
|
| Radiography | 2 | 2014 | 572 | 0.220 |
Why?
|
| Thermodilution | 1 | 2022 | 20 | 0.220 |
Why?
|
| Incidence | 4 | 2021 | 1603 | 0.220 |
Why?
|
| Puerperal Disorders | 1 | 2022 | 20 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 24 | 0.200 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.200 |
Why?
|
| Pulmonary Circulation | 2 | 2021 | 79 | 0.200 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 41 | 0.200 |
Why?
|
| Surgeons | 1 | 2022 | 68 | 0.200 |
Why?
|
| Angiopoietin-2 | 1 | 2021 | 5 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2021 | 91 | 0.190 |
Why?
|
| Atrial Pressure | 1 | 2020 | 9 | 0.190 |
Why?
|
| Inhalation | 1 | 2020 | 11 | 0.190 |
Why?
|
| Myocarditis | 1 | 2021 | 49 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 274 | 0.180 |
Why?
|
| Time Factors | 5 | 2022 | 4655 | 0.180 |
Why?
|
| Heart Rate | 2 | 2020 | 568 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2021 | 85 | 0.180 |
Why?
|
| Ventricular Pressure | 1 | 2020 | 82 | 0.180 |
Why?
|
| Sildenafil Citrate | 1 | 2020 | 23 | 0.180 |
Why?
|
| Thrombosis | 1 | 2021 | 218 | 0.180 |
Why?
|
| Pacemaker, Artificial | 1 | 2021 | 157 | 0.170 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 164 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1851 | 0.170 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.170 |
Why?
|
| Cardiotonic Agents | 2 | 2020 | 71 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 2324 | 0.170 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2019 | 9 | 0.170 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 25 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2020 | 113 | 0.170 |
Why?
|
| Survival Rate | 5 | 2021 | 1056 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2020 | 221 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2022 | 400 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1465 | 0.160 |
Why?
|
| Obesity | 3 | 2022 | 1076 | 0.160 |
Why?
|
| Acute Disease | 2 | 2019 | 658 | 0.150 |
Why?
|
| Exercise Test | 4 | 2021 | 242 | 0.150 |
Why?
|
| Patient Selection | 2 | 2019 | 592 | 0.150 |
Why?
|
| Biomarkers | 2 | 2022 | 1593 | 0.150 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.150 |
Why?
|
| Disease Management | 2 | 2018 | 248 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2017 | 46 | 0.150 |
Why?
|
| Nausea | 1 | 2017 | 47 | 0.140 |
Why?
|
| Pedigree | 1 | 2017 | 159 | 0.140 |
Why?
|
| Focus Groups | 1 | 2018 | 247 | 0.140 |
Why?
|
| Logistic Models | 2 | 2021 | 1420 | 0.140 |
Why?
|
| Diarrhea | 1 | 2017 | 63 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 49 | 0.140 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 9 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 189 | 0.140 |
Why?
|
| Proteinuria | 1 | 2017 | 136 | 0.140 |
Why?
|
| Prosthesis Design | 1 | 2018 | 301 | 0.140 |
Why?
|
| Body Temperature | 1 | 2017 | 116 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2018 | 109 | 0.140 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2016 | 25 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 121 | 0.140 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 25 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 492 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 498 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 39 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2022 | 2358 | 0.130 |
Why?
|
| Natriuretic Agents | 1 | 2015 | 9 | 0.130 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 57 | 0.130 |
Why?
|
| Chromogranins | 1 | 2014 | 4 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 9 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1753 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 232 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 15 | 0.120 |
Why?
|
| Heart | 2 | 2016 | 850 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 2223 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2016 | 183 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1330 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 839 | 0.120 |
Why?
|
| Ganciclovir | 1 | 2014 | 27 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 453 | 0.110 |
Why?
|
| Dyspnea | 1 | 2014 | 87 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2014 | 115 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2014 | 168 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1615 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2016 | 342 | 0.110 |
Why?
|
| Young Adult | 2 | 2021 | 5717 | 0.110 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2012 | 5 | 0.100 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2012 | 5 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2014 | 171 | 0.100 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 25 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2014 | 204 | 0.100 |
Why?
|
| Mycophenolic Acid | 1 | 2012 | 62 | 0.100 |
Why?
|
| Prednisone | 1 | 2012 | 104 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 211 | 0.100 |
Why?
|
| Sodium Benzoate | 1 | 2011 | 1 | 0.100 |
Why?
|
| Phenylacetates | 1 | 2011 | 18 | 0.100 |
Why?
|
| Carbohydrates | 1 | 2011 | 57 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 346 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 407 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2011 | 174 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 157 | 0.080 |
Why?
|
| Compliance | 2 | 2020 | 26 | 0.080 |
Why?
|
| Glucose | 1 | 2011 | 307 | 0.080 |
Why?
|
| Lung | 1 | 2014 | 849 | 0.080 |
Why?
|
| Insulin | 1 | 2011 | 619 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2019 | 714 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 792 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1054 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 978 | 0.060 |
Why?
|
| Brain | 1 | 2016 | 2176 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2077 | 0.060 |
Why?
|
| X-Rays | 1 | 2022 | 56 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2022 | 15 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2022 | 99 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 101 | 0.050 |
Why?
|
| Angiopoietins | 1 | 2021 | 4 | 0.050 |
Why?
|
| Angiopoietin-1 | 1 | 2021 | 12 | 0.050 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2021 | 20 | 0.050 |
Why?
|
| Heparin | 1 | 2021 | 205 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 83 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 117 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 229 | 0.050 |
Why?
|
| Milrinone | 1 | 2020 | 12 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2022 | 195 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 295 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 483 | 0.040 |
Why?
|
| Elasticity | 1 | 2019 | 103 | 0.040 |
Why?
|
| Biological Availability | 1 | 2019 | 79 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 2019 | 59 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 356 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 49 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 867 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 107 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 1515 | 0.040 |
Why?
|
| Netherlands | 1 | 2017 | 68 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 205 | 0.040 |
Why?
|
| Animals | 1 | 2015 | 20881 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 50 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 349 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 945 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 320 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1426 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 238 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 392 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 127 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 465 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 500 | 0.030 |
Why?
|
| American Heart Association | 1 | 2014 | 142 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1864 | 0.030 |
Why?
|
| Life Style | 1 | 2014 | 338 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1738 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2014 | 340 | 0.030 |
Why?
|
| Decompression, Surgical | 1 | 2012 | 55 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 567 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 504 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 481 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 694 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 1535 | 0.020 |
Why?
|